Venture capital firm Earlybird has launched a €173 million fund to invest in biopharma and digital health startups across Europe. The fund comes as pharmaceutical companies face an approaching patent cliff in 2030, increasing the demand for innovative drug development and digital healthcare solutions.

With this new capital, Earlybird aims to support startups in AI-powered drug discovery, precision medicine, and diagnostics, further strengthening Germany’s healthtech ecosystem.

🔗 Read more: Sifted